Partnership to accelerate development of lead product candidate, RO-104; a first-in-class tri-specific biologic for treating neovascular age-relat...
Alvotech a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz P...
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, is embracing the theme of the 60th annual Drug ...
AbbVie and FutureGen Biopharmaceutical (Beijing) Co., Ltd. announced a license agreement to develop FG-M701, a next generation TL1A antibody for th...
Eisai Co., and Biogen announced that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s Supplemental Biologics License Applicat...
HUTCHMED (China) announces that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hematological malignancies in Ch...
Bio-Thera Solutions , a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, announced th...
START is a pilot program newly launched jointly by the FDA CDER and CBER divisions to further accelerate the development of novel drug and biological p...
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has launched its M...
Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong ...
Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review gran...
Bristol Myers Squibb announced its participation in the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the Eur...
Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia® EC a...
CUPID is a Phase I safety and dosimetry study of TLX592, Telix’s investigational antibody-based targeted alpha therapy for prostate cancer. Establ...
© 2025 Biopharma Boardroom. All Rights Reserved.
